Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 1Breast 1

Conditions

Breast Neoplasms 12Neoplasms 4Recurrence 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hereditary Sensory and Autonomic Neuropathies 1HR+/HER2- Breast Cancer 1Glioma 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Diseases 1

Interventions

pembrolizumab 19Cisplatin 18Cetuximab 13Carboplatin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Docetaxel 8Radiotherapy, Intensity-Modulated 7Paclitaxel 7Nivolumab 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Radiotherapy 5dostarlimab 4atezolizumab 4Immunoglobulin G 4Fluorouracil 4Disulfides 4Biopsy 4(225)Ac-DOTA-c(RGDyK) 4Radiation 3Bevacizumab 3cemiplimab 2amivantamab 2abemaciclib 2Taxes 2Fulvestrant 2130-nm albumin-bound paclitaxel 2zimberelimab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × abemaciclib × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT04169074 2026-05-22

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

University of Arizona

Phase 2 Terminated
7 enrolled 14 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡